Mesoblast (MESO) had the highest return in 2010 by a US stock in the Biotechnology Industry, returning 15,946,566.7%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Mesoblast (MESO) | 2010 | 15,946,566.67% |
Evogene (EVGN) | 2010 | 4,479,900% |
Altimmune (ALT) | 2010 | 750% |
Edesa Biotech (EDSA) | 2010 | 615% |
Amarin (AMRN) | 2010 | 473.43% |
XTL Biopharmaceuticals Ltd ADR (XTLB) | 2010 | 323.42% |
iBio, Inc Common Stock (IBIO) | 2010 | 251.11% |
BioRestorative Therapies (BRTX) | 2010 | 246.15% |
Galectin Therapeutics (GALT) | 2010 | 221.43% |
MDxHealth SA ADR (MDXH) | 2010 | 216.67% |
Neurocrine Biosciences (NBIX) | 2010 | 175.81% |
Vera Therapeutics (VERA) | 2010 | 160% |
Oncolytics Biotech (ONCY) | 2010 | 150% |
Enveric Biosciences (ENVB) | 2010 | 123.88% |
Opko Health (OPK) | 2010 | 103.89% |
Lineage Cell Therapeutics (LCTX) | 2010 | 89.75% |
Theriva Biologics (TOVX) | 2010 | 89.39% |
MiMedx (MDXG) | 2010 | 84.93% |
Incyte (INCY) | 2010 | 79.61% |
NanoViricides (NNVC) | 2010 | 70.93% |
Emergent Biosolutions (EBS) | 2010 | 70.62% |
Arrowhead Pharmaceuticals (ARWR) | 2010 | 68.87% |
Anavex Life Sciences (AVXL) | 2010 | 65.91% |
Agenus (AGEN) | 2010 | 57.82% |
Catalyst Pharmaceuticals (CPRX) | 2010 | 55.91% |